Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile - Neurocrine Biosciences ( NASDAQ:NBIX )
On Monday, Neurocrine Biosciences, Inc. ( NASDAQ:NBIX ) said its Phase 2 study of NBI-1070770 in adults with major depressive disorder did not meet the primary endpoint compared to placebo, though it was generally well tolerated.
Looking for a Growth Stock? 3 Reasons Why Neurocrine ( NBIX ) is a Solid Choice
Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.
Zoom To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Tuesday - Bullish ( NYSE:BLSH ) , Appian ( NASDAQ:APPN )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Baird raised RealReal Inc ( NASDAQ:REAL ) price target from $8 to $13.
Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- Transition Bio, a drug discovery company focused on unlocking traditionally "undruggable" targets by leveraging biomolecular condensates, and Voyager Therapeutics ( Nasdaq: VYGR ) , a biotechnology company ...
Voyager Reports Third Quarter 2025 Financial and Operating Results
- Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in ...
Earnings Estimates Rising for Neurocrine ( NBIX ) : Will It Gain?
Neurocrine Biosciences (NBIX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
What Makes Neurocrine ( NBIX ) a New Strong Buy Stock
Neurocrine (NBIX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
XENE reports narrower-than-expected Q3 loss as the biotech advances multiple late-stage studies of azetukalner across epilepsy and mood disorders.
S&P 500 Tops 6,900 Ahead Fed Rate Move, Gold Reclaims $4,000 - iShares Semiconductor ETF ( NASDAQ:SOXX )
A powerful surge in AI-related stocks - led by a 9% advance in NVIDIA Corp. ( NASDAQ:NVDA ) over the past two sessions - propelled the S&P 500 above the 6,900 mark and lifted the Nasdaq 100 to 26,100 points, both breaking new records, as investors brace for the Federal Reserve's highly ...
Neurocrine Biosciences ( NBIX ) Q3 Earnings and Revenues Top Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of +29.11% and +6.73%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Are You Looking for a Top Momentum Pick? Why Neurocrine Biosciences ( NBIX ) is a Great Choice
Does Neurocrine Biosciences (NBIX) have what it takes to be a top stock pick for momentum investors? Let's find out.
3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine ( NBIX )
Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.
USANA Health Sciences ( USNA ) Reports Q3 Loss, Misses Revenue Estimates
USANA Health (USNA) delivered earnings and revenue surprises of 0.00% and -0.10%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics ( UTHR ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine Biosciences ( NBIX ) Reports Next Week: Wall Street Expects Earnings Growth
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Global Anti-Parkinson's Drugs Markets Projected to Reach $9.2 Billion by the End of 2030
Boston, Oct. 16, 2025 ( GLOBE NEWSWIRE ) -- According to the latest study from BCC Research, "Anti-Parkinson's Drugs: Global Markets to 2030" is projected to grow from $6.1 billion in 2025 to $9.2 billion by the end of 2030, at a compound annual growth rate ( CAGR ) of 8.6% from 2025 to 2030.
GRFS or NBIX: Which Is the Better Value Stock Right Now?
GRFS vs. NBIX: Which Stock Is the Better Value Option?
Voyager to Present at Upcoming Investor Conferences
LEXINGTON, Mass., Aug. 26, 2025 ( GLOBE NEWSWIRE ) -- Voyager Therapeutics, Inc. ( Nasdaq: VYGR ) , a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences: ...
Voyager to Present at Upcoming Investor Conferences - Voyager Therapeutics ( NASDAQ:VYGR )
LEXINGTON, Mass., Aug. 26, 2025 ( GLOBE NEWSWIRE ) -- Voyager Therapeutics, Inc. VYGR, a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences:
GRFS or NBIX: Which Is the Better Value Stock Right Now?
GRFS vs. NBIX: Which Stock Is the Better Value Option?
Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus
XENE's wider Q2 loss highlights its push toward late-stage epilepsy, depression, and bipolar disorder studies with azetukalner.
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025
Tokyo, Japan and Cambridge, UK, 8 August 2025 - Nxera Pharma ( "the Company" or "Nxera". TSE: 4565 ) provides an update on operational activities and reports its consolidated results for the second quarter and first half ended 30 June 2025. The full report can be found here.
Neurocrine ( NBIX ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Wednesday, July 30, 2025 at 8:30 p.m. ETChief Executive Officer - Kyle J. GanoContinue reading ...
Neurocrine ( NBIX ) Q2 Revenue Jumps 17%
Neurocrine Biosciences ( NASDAQ:NBIX ) , a neuroscience-focused biopharma company, delivered a standout earnings report for the second quarter of fiscal 2025, released on July 30, 2025. The report revealed substantial outperformance: Non-GAAP diluted earnings per share reached $1.65, topping ...
Neurocrine Biosciences ( NBIX ) Q2 Earnings and Revenues Beat Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of +8.16% and +5.72%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
CPRX vs. NBIX: Which Stock Should Value Investors Buy Now?
CPRX vs. NBIX: Which Stock Is the Better Value Option?
Indivior PLC ( INDV ) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Indivior (INDV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine Biosciences ( NBIX ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach
- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant ...
Is First Trust NYSE Arca Biotechnology ETF ( FBT ) a Strong ETF Right Now?
Smart Beta ETF report for ...
CPRX vs. NBIX: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical ( CPRX Quick QuoteCPRX - ) and Neurocrine Biosciences ( NBIX Quick QuoteNBIX - ) . But which of these two stocks offers value investors a better bang for their buck right now?
Should You Invest in the First Trust NYSE Arca Biotechnology ETF ( FBT ) ?
Sector ETF report for ...
NetraMark Founder Coauthors New Publication on AI/ML Use in Clinical Trials, Alongside Authors From Leading Global Regulatory Organizations - NetraMark Holdings ( OTC:AINMF )
TORONTO, June 12, 2025 ( GLOBE NEWSWIRE ) -- NetraMark Holdings Inc. ( the "Company" or "NetraMark" ) AIAI AINMF PF, an artificial intelligence ( AI ) solutions company transforming clinical trial design in the pharmaceutical industry through streamlined access to actionable analytics uncovered ...
NetraMark Founder Coauthors New Publication on AI/ML Use in Clinical Trials, Alongside Authors From Leading Global Regulatory Organizations
TORONTO, June 12, 2025 ( GLOBE NEWSWIRE ) -- NetraMark Holdings Inc. ( the "Company" or "NetraMark" ) ( CSE: AIAI ) ( OTCQB: AINMF ) ( Frankfurt: PF0 ) , an artificial intelligence ( AI ) solutions company transforming clinical trial design in the pharmaceutical industry through streamlined ...
Should You Invest in the SPDR S&P Biotech ETF ( XBI ) ?
Sector ETF report for ...
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - Voyager Therapeutics ( NASDAQ:VYGR )
LEXINGTON, Mass., June 10, 2025 ( GLOBE NEWSWIRE ) -- Voyager Therapeutics, Inc. VYGR, a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced Alfred W.
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
LEXINGTON, Mass., June 10, 2025 ( GLOBE NEWSWIRE ) -- Voyager Therapeutics, Inc. ( Nasdaq: VYGR ) , a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager, and additional ...
CPRX or NBIX: Which Is the Better Value Stock Right Now?
CPRX vs. NBIX: Which Stock Is the Better Value Option?
Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568
Tokyo, Japan and Cambridge, UK, 3 June 2025 - Nxera Pharma Co., Ltd. ( "Nxera" or "the Company". TSE 4565 ) today announces that its partner, Neurocrine Biosciences ( "Neurocrine" ) has dosed the first patient in its Phase 3 registrational program of NBI-1117568 ( NBI-'568 ) as a potential ...
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors - Neurocrine Biosciences ( NASDAQ:NBIX ) , Fate Therapeutics ( NASDAQ:FATE )
SAN DIEGO, May 30, 2025 ( GLOBE NEWSWIRE ) -- Fate Therapeutics, Inc. FATE, a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell ( iPSC ) -derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Matthew ...
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
SAN DIEGO, May 30, 2025 ( GLOBE NEWSWIRE ) -- Fate Therapeutics, Inc. ( NASDAQ: FATE ) , a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell ( iPSC ) -derived off-the-shelf cellular immunotherapies to patients, today announced the ...
Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
Tokyo, Japan and Cambridge, UK, 29 May 2025 - Nxera Pharma Co., Ltd. ( "Nxera" or "the Company". TSE 4565 ) notes that Neurocrine Biosciences, Inc. announced that it had presented new positive data from the Phase 2 study of NBI-1117568 in adults with schizophrenia at the American Society of ...
Should You Invest in the Invesco Biotechnology & Genome ETF ( PBE ) ?
Sector ETF report for ...
Is Janus Henderson Small/Mid Cap Growth Alpha ETF ( JSMD ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Insider Decision Making Waves At Neurocrine Biosciences: CHARLES KEVIN GORMAN Exercises Options, Realizing $0 - Neurocrine Biosciences ( NASDAQ:NBIX )
A large exercise of company stock options by CHARLES KEVIN GORMAN, Board Member at Neurocrine Biosciences NBIX was disclosed in a new SEC filing on May 22, as part of an insider exercise. What Happened: A Form 4 filing from the U.S.
Is Invesco Biotechnology & Genome ETF ( PBE ) a Strong ETF Right Now?
Smart Beta ETF report for ...
GRFS or NBIX: Which Is the Better Value Stock Right Now?
GRFS vs. NBIX: Which Stock Is the Better Value Option?
Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication - Voyager Therapeutics ( NASDAQ:VYGR )
LEXINGTON, Mass., May 15, 2025 ( GLOBE NEWSWIRE ) -- Voyager Therapeutics, Inc. VYGR, a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first peer-reviewed publication of data demonstrating the ability of alkaline phosphatase ( ALPL ) to ...
Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication
LEXINGTON, Mass., May 15, 2025 ( GLOBE NEWSWIRE ) -- Voyager Therapeutics, Inc. ( Nasdaq: VYGR ) , a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first peer-reviewed publication of data demonstrating the ability of alkaline ...
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus
XENE incurs narrower-than-estimated first-quarter 2025 loss. Studies on lead candidate, azetukalner, in epilepsy and MDD are progressing well.
